Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.46 |
| ▸ | NAMPT | P43490 | 3/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | KIT | P10721 | 1/20 | 0.41 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.41 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | SGMS1 | Q86VZ5 | 1/20 | 0.41 |
| ▸ | NPY1R | P25929 | 1/20 | 0.40 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.40 |
| ▸ | NSD2 | O96028 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14334349 | 0.91 | KEAP1 (0.48) | CA1CA2CA9NAMPTSMN1; SMN2 | |
| SCHEMBL14333772 | 0.83 | SMN1; SMN2 (0.53) | CA1CA2CA9SMN1; SMN2HTT | |
| SCHEMBL14992892 | 0.81 | SMN1; SMN2 (0.47) | CA1CA2SMN1; SMN2HTTLMNA | |
| SCHEMBL4508326 | 0.81 | CYP19A1 (0.50) | CYP19A1SMN1; SMN2HTTALDH1A1NPY1R | |
| SCHEMBL15643222 | 0.80 | ADAMTS4 (0.51) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL15819472 | 0.78 | HTT (0.50) | CA1CA2CA9SMN1; SMN2HTT | |
| SCHEMBL3258403 | 0.78 | NPY1R (0.42) | NAMPTSMN1; SMN2HTTNPY1RNPY5R | |
| SCHEMBL15841261 | 0.77 | HTT (0.48) | SMN1; SMN2HTTLMNAALDH1A1NPY1R | |
| SCHEMBL14334759 | 0.77 | AR (0.53) | CYP19A1SMN1; SMN2HTTALDH1A1SGMS1 | |
| SCHEMBL15643545 | 0.75 | CYP19A1 (0.44) | CYP19A1SMN1; SMN2HTTLMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140113934-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING HELMINTH INFECTIONS | E I DU PONT DE NEMOURS AND COMPANY (US) | 2014-04-24 | — | — | US | claimed |
| EP-2721006-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING HELMINTH INFECTIONS | E. I. Du Pont de Nemours and Company (US) | 2014-04-23 | — | — | EP | claimed |
| WO-2012177668-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING HELMINTH INFECTIONS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2012-12-27 | — | — | WO | claimed |
| US-20140113934-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING HELMINTH INFECTIONS | E I DU PONT DE NEMOURS AND COMPANY (US) | 2014-04-24 | — | — | US | disclosed |
| EP-2721006-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING HELMINTH INFECTIONS | E. I. Du Pont de Nemours and Company (US) | 2014-04-23 | — | — | EP | disclosed |
| WO-2012177668-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING HELMINTH INFECTIONS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2012-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140113934-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING HELMINTH INFECTIONS | NR5A2, NR2C2, NPY5R | CYP19A1 686/4885CA1 1605/4885CA2 1233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.